Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.31 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27176187 | 0.81 | PRKACA (0.45) | TDO2IDO1PIK3CDPRKACAPRKACG | |
| SCHEMBL12498325 | 0.78 | EGLN2 (0.36) | TDO2IDO1EGLN2ALDH1A1SMN1; SMN2 | |
| SCHEMBL15651144 | 0.78 | PIK3CD (0.38) | TDO2IDO1PIK3CDPRKACAPRKACG | |
| SCHEMBL3441130 | 0.75 | PIK3CD (0.36) | TDO2IDO1PIK3CDPRKACAPRKACG | |
| SCHEMBL26331236 | 0.75 | CSNK1A1 (0.37) | TDO2IDO1PIK3CDPRKACAPRKACG | |
| SCHEMBL3095407 | 0.75 | KDM4E (0.40) | TDO2IDO1EGLN2ALDH1A1SMN1; SMN2 | |
| SCHEMBL29672973 | 0.75 | KDM4E (0.40) | TDO2IDO1EGLN2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2596919 | 0.75 | TDO2 (0.36) | TDO2IDO1EGLN2ERBB2 | |
| SCHEMBL2881406 | 0.75 | CCR1 (0.35) | TDO2IDO1EGLN2ALDH1A1SMN1; SMN2 | |
| SCHEMBL14842294 | 0.75 | TDO2 (0.33) | TDO2IDO1EGLN2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-10077264-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3240787-A2 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | TDO2 3416/4885IDO1 1028/4885PIK3CD 3866/4885 |
| US-10077264-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | TDO2 3416/4885IDO1 1028/4885PIK3CD 3866/4885 |
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | TDO2 3416/4885IDO1 1028/4885PIK3CD 3866/4885 |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | TDO2 3416/4885IDO1 1028/4885PIK3CD 3866/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | TDO2 3416/4885IDO1 1028/4885PIK3CD 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.